Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitriol for prevention of acute rejection after liver transplantation
IRCT20260105068556N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of calcitriol in Hepatic transplant rejection (LTR) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Incidence of acute cellular rejection. Started Feb 2026; status: completed.
02
Drugs
calcitriol
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on IRCT20260105068556N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260105068556N1.